# The Effects of Glucose Control and Weight Loss Between Beinaglutide and Dulaglutide in Type 2 Diabetes With Overweight or Obesity.

Study · id `cardio:ct-nct05005741` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT05005741](<https://clinicaltrials.gov/study/NCT05005741>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT05005741

Browse, organ or system: Metabolism  
Browse, condition area: Diabetes and metabolic disease  

## In plain language

A phase 4 trial registered on ClinicalTrials.gov. The registry status is unknown. It plans to enroll 120 participants.

## Technical summary

Registry record NCT05005741. Randomized; no masking; primary purpose treatment. Start 2021-05-01 (actual); primary completion 2023-12-31 (anticipated). Results not posted.

## Key facts

- Design: Interventional study; randomized; no masking; primary purpose treatment
- Phase: Phase 4
- Enrolled: 120 participants (planned count; ClinicalTrials.gov record NCT05005741, source copy `cardio:ctgov-nct05005741-2023-03-17`, retrieved 2026-10-26)
- Started: 2021-05-01 (actual) (ClinicalTrials.gov record NCT05005741, source copy `cardio:ctgov-nct05005741-2023-03-17`, retrieved 2026-10-26)
- Primary completion: 2023-12-31 (anticipated) (ClinicalTrials.gov record NCT05005741, source copy `cardio:ctgov-nct05005741-2023-03-17`, retrieved 2026-10-26)
- Completion: 2023-12-31 (anticipated) (ClinicalTrials.gov record NCT05005741, source copy `cardio:ctgov-nct05005741-2023-03-17`, retrieved 2026-10-26)
- Countries: China (ClinicalTrials.gov record NCT05005741, source copy `cardio:ctgov-nct05005741-2023-03-17`, retrieved 2026-10-26)
- Care setting: Not reported
- Registry status: "UNKNOWN" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct05005741-2023-03-17`, retrieved 2026-10-26)

## The registry's words

- Brief title: The Effects of Glucose Control and Weight Loss Between Beinaglutide and Dulaglutide in Type 2 Diabetes With Overweight or Obesity.
- Condition: Diabetes Mellitus, Type 2
- Condition: Overweight or Obesity
- Intervention (Drug): Beinaglutide
- Intervention (Drug): Dulaglutide
- Lead sponsor: Second Xiangya Hospital of Central South University
- Lead sponsor class: OTHER
- Collaborator: Guangdong Provincial People's Hospital
- Collaborator class: OTHER
- Collaborator: First Affiliated Hospital of Harbin Medical University
- Collaborator class: OTHER
- Collaborator: The First Affiliated Hospital of Henan University of Science and Technology
- Collaborator class: OTHER

## Connected pages

- Registry condition terms include this condition: Type 2 diabetes (`cardio:type-2-diabetes`)
- Registry lists this organization as the lead sponsor: Second Xiangya Hospital of Central South University (`cardio:org-second-xiangya-hospital-of-central-south-university`)
- Registry lists this organization as a collaborator: Guangdong Provincial People's Hospital (`cardio:org-guangdong-provincial-people-s-hospital`)
- Registry lists this organization as a collaborator: First Affiliated Hospital of Harbin Medical University (`cardio:org-first-affiliated-hospital-of-harbin-medical-university`)

## Provenance

Content hash: 6527cced9ba6f2a125e5f01637f283fdb3fb0c65a708a7c6c672fed1cd2ff56b
Last substantive edit: 2026-11-08
Evidence last checked: Not recorded
